---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-302201"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:15:33.623386+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Arcellx and Kite Pharma enter CAR T-cell therapy collaboration; $225M upfront + $100M equity

## Summary
- Collaboration and License Agreement with Kite Pharma (Gilead) for CART-ddBCMA, a CAR T therapy for myeloma.
- Arcellx receives $225M upfront cash payment and $100M equity investment from Kite.
- Eligible for milestones up to $635M per NextGen Product and $508M per Non-Auto Product.
- Arcellx retains co-development/co-commercialization option and royalties on Licensed Products.
- Deal subject to HSR review and other regulatory approvals.

## SEC filing metadata
- accession: 0001193125-22-302201
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312522302201/0001193125-22-302201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312522302201/d378409d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-302201
- JSON: https://secwatch.observer/filing/0001193125-22-302201.json
- Plain text: https://secwatch.observer/filing/0001193125-22-302201.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.